Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles D Blanke

Showing results (61-70 of 152) with videos related to

Pageof 16
Sort By:
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2024
Pragmaticism in Cancer Clinical TrialsKamya Sankar, Mary W Redman, Konstantin H Dragnev, et al.
Investigational New Drugs|July 13, 2011
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinomaAnthony B El-Khoueiry, Cathryn J Rankin, Edgar Ben-Josef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2011
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trialsCharles D Blanke, Brian M Bot, David M Thomas, et al.
American Journal of Clinical Oncology|April 8, 2006
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trialStephen K Williamson, Sheryl A McCoy, David R Gandara, et al.
American Journal of Clinical Oncology|September 23, 2009
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomachCharles D Blanke, Kari Chansky, Kathy L Christman, et al.
Journal of Surgical Oncology|October 23, 2008
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665Burton L Eisenberg, Jonathan Harris, Charles D Blanke, et al.
Clinical Colorectal Cancer|July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT databaseWinson Y Cheung, Qian Shi, Michael O'Connell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Seminars in Oncology|October 5, 2015
The Globalization of Cooperative GroupsManuel Valdivieso, Benjamin W Corn, Janet E Dancey, et al.
Pageof 16

Showing results (61-70 of 152) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2024
Pragmaticism in Cancer Clinical TrialsKamya Sankar, Mary W Redman, Konstantin H Dragnev, et al.
Investigational New Drugs|July 13, 2011
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinomaAnthony B El-Khoueiry, Cathryn J Rankin, Edgar Ben-Josef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2011
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trialsCharles D Blanke, Brian M Bot, David M Thomas, et al.
American Journal of Clinical Oncology|April 8, 2006
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trialStephen K Williamson, Sheryl A McCoy, David R Gandara, et al.
American Journal of Clinical Oncology|September 23, 2009
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomachCharles D Blanke, Kari Chansky, Kathy L Christman, et al.
Journal of Surgical Oncology|October 23, 2008
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665Burton L Eisenberg, Jonathan Harris, Charles D Blanke, et al.
Clinical Colorectal Cancer|July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT databaseWinson Y Cheung, Qian Shi, Michael O'Connell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Seminars in Oncology|October 5, 2015
The Globalization of Cooperative GroupsManuel Valdivieso, Benjamin W Corn, Janet E Dancey, et al.
Pageof 16